Bottom line
Is ELIS a good fund? The bottom line
ELIS is a managed leveraged & inverse ETF from Direxion.
Annual fees run 1.01% — about $101 a year on every $10,000 invested, cheaper than 71% of leveraged & inverse funds we track.
Updated Nov 19, 2026
What ELIS invests in
The Fund seeks daily investment results, before fees and expenses, of 100% of the inverse (or opposite) of the daily performance of LLY. The Fund does not seek to achieve its stated investment objective for a period of time different than a trading day.
The Fund, under normal circumstances, invests at least 80% of the Funds net assets (plus borrowings for investment purposes) in financial instruments, including swap agreements and options, that, in combination, provide 1X daily inverse (opposite) or short exposure to LLY, consistent with the Funds investment objective. Eli Lilly and Company is a global pharmaceutical company dedicated to discovering, developing, manufacturing, and marketing innovative medicines in various therapeutic areas, including neuroscience, endocrinology, oncology, cardiovascular diseases, and immunology. Its portfolio encompasses a wide range of prescription drugs, biologics, and animal health products. LLY is registered under the Securities Exchange Act of 1934, as amended (the Exchange Act). Information provided to or filed with the Securities and Exchange Commission by Eli Lilly and Company pursuant to the…
From the fund's prospectus (filed Mar 3, 2026).
What ELIS costs
On a $10,000 investment, ELIS's 1.01% expense ratio costs about $101 a year. The prospectus estimates $2,238 in total costs over 10 years (assuming 5% annual returns). The median leveraged & inverse fund charges 1.31%.